ARX788 has been given a fast track designation by the U.S. Food and Drug Administration as a monotherapy for patients with HER2-positive metastatic breast cancer previously treated with at least one anti-HER2-based regimen. The designation helps to accelerate the clinical development and expedite the approval of promising therapies for serious diseases, by providing more frequent meetings with the FDA and discussions about therapy development. “This is an important milestone for ARX788 that underscores the strong…
You must be logged in to read/download the full post.
The post ARX788 on FDA Fast Track for Advanced HER2-positive Breast Cancers appeared first on BioNewsFeeds.